George S, Braithwaite R A
Regional Laboratory for Toxicology, Birmingham City Hospital NHS Trust, UK.
Addiction. 1995 Jul;90(7):967-70.
Recent American and Swedish studies have shown an increase in "false" negative results when analysing dilute urine specimens for drugs of abuse. In the light of these studies, it was decided to perform a pilot study to determine the extent of possible specimen adulteration and dilution in a random batch of 50 urine specimens presented to this laboratory, using creatinine, osmolality, pH and relative density. It was found that 20% of the specimens were outside the pH range associated with the optimum working of Syva EMIT Drugs of Abuse in Urine (DAU) immunoassay screening techniques, and that if the National Institute on Drug Abuse (NIDA) recognized dilution cut-off of 1.8 mmol/L for urine creatinine concentration is applied, 84% of the specimens surveyed here would need to be repeated to ensure accurate results. Because of these findings, it is recommended that routine creatinine and pH estimations should be performed on all specimens submitted for urinary drugs of abuse screening, or at least when unexpectedly negative results are obtained.
近期美国和瑞典的研究表明,在分析稀释尿液样本中的滥用药物时,“假”阴性结果有所增加。鉴于这些研究,决定进行一项初步研究,以使用肌酐、渗透压、pH值和相对密度来确定提交至本实验室的随机抽取的50份尿液样本中可能存在的样本掺假和稀释程度。结果发现,20%的样本超出了与赛瓦尿液滥用药物(DAU)免疫分析筛查技术最佳工作状态相关的pH范围,并且如果应用美国国家药物滥用研究所(NIDA)认可的尿液肌酐浓度1.8 mmol/L的稀释临界值,此处所调查的84%的样本需要重新检测以确保结果准确。基于这些发现,建议对所有提交进行尿液滥用药物筛查的样本进行常规肌酐和pH值测定,或者至少在获得意外阴性结果时进行测定。